Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7636547rdf:typepubmed:Citationlld:pubmed
pubmed-article:7636547lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C1514474lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C1317973lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C0242792lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C0183683lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C0344211lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C1521721lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C1328050lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C0439590lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:7636547lifeskim:mentionsumls-concept:C1171411lld:lifeskim
pubmed-article:7636547pubmed:issue8lld:pubmed
pubmed-article:7636547pubmed:dateCreated1995-9-11lld:pubmed
pubmed-article:7636547pubmed:abstractTextWith a median observation time of 50 months from transplant, 13 (22%) of 62 women with metastatic breast cancer treated with high-dose chemotherapy at the Dana-Farber Cancer Institute (DFCI)/Beth Israel Hospital (BIH) remain progression-free. This study determined factors prognostic for prolonged progression-free survival (PFS).lld:pubmed
pubmed-article:7636547pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7636547pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7636547pubmed:languageenglld:pubmed
pubmed-article:7636547pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7636547pubmed:citationSubsetIMlld:pubmed
pubmed-article:7636547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7636547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7636547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7636547pubmed:statusMEDLINElld:pubmed
pubmed-article:7636547pubmed:monthAuglld:pubmed
pubmed-article:7636547pubmed:issn0732-183Xlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:SchwartzGGlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:FreiEE3rdlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:ReichEElld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:EliasAAlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:WheelerCClld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:WarrenDDlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:FaircloughDDlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:AntmanKKlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:AyashL JLJlld:pubmed
pubmed-article:7636547pubmed:authorpubmed-author:SchnipperLLlld:pubmed
pubmed-article:7636547pubmed:issnTypePrintlld:pubmed
pubmed-article:7636547pubmed:volume13lld:pubmed
pubmed-article:7636547pubmed:ownerNLMlld:pubmed
pubmed-article:7636547pubmed:authorsCompleteYlld:pubmed
pubmed-article:7636547pubmed:pagination2043-9lld:pubmed
pubmed-article:7636547pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:meshHeadingpubmed-meshheading:7636547-...lld:pubmed
pubmed-article:7636547pubmed:year1995lld:pubmed
pubmed-article:7636547pubmed:articleTitlePrognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.lld:pubmed
pubmed-article:7636547pubmed:affiliationDana-Farber Cancer Institute, Beth Israel Hospital, Harvard Medical School, Boston, MA, USA.lld:pubmed
pubmed-article:7636547pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7636547pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7636547pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7636547pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7636547lld:pubmed